<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350620</url>
  </required_header>
  <id_info>
    <org_study_id>CP-NVK002-0001</org_study_id>
    <secondary_id>2018-001077-24</secondary_id>
    <nct_id>NCT03350620</nct_id>
  </id_info>
  <brief_title>CHAMP: Study of NVK-002 in Children With Myopia</brief_title>
  <official_title>A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nevakar, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nevakar, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to
      Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment
      period.

      Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of
      treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive
      myopia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 3-arm randomized, multicenter, double-masked, placebo-controlled study
      conducted in 2 stages.

      Stage 1 is a safety and efficacy phase of 3 years in duration, during which subjects will be
      allocated to 1 of 3 study medications.

      Stage 2 is a randomized cross-over phase of 1 year in duration, during which subjects will be
      re-randomized to receive 1 of the 3 study medications, with subjects initially randomized to
      Vehicle only eligible for randomization to low or high-dose NVK-002.

      Treatment arms are:

        -  NVK-002 low dose concentration

        -  NVK-002 high dose concentration

        -  Vehicle (placebo)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be a 3-arm randomized, multicenter, double-masked, placebo-controlled study conducted in 2 stages.
Stage 1 is a safety and efficacy phase of 3 years in duration, during which subjects will be allocated to 1 of 3 study medications.
Stage 2 is a randomized cross-over phase of 1 year in duration, during which subjects will be re-randomized to receive 1 of the 3 study medications with subjects initially randomized to Vehicle only eligible for randomization to low or high dose NVK-002.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>If subjects meet eligibility criteria at the Screening/Baseline visit (Day 0), subjects will be randomly assigned to masked study medication.
The study will be double masked. The study medication will be provided in identical-appearing laminated pouches with no labeling indicating the identity of the study group or the contents of the ampules. The laminated pouches will contain identical-appearing ampules. Study subjects and study management personnel will be masked to the identity of treatment until after the final database lock.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The overall between-group difference in proportion of subjects who show &lt; -0.50 D myopia progression (SER) at the Month 36 visit.</measure>
    <time_frame>36 Months</time_frame>
    <description>The overall between-group difference in proportion of subjects who show &lt; -0.50 D myopia progression (SER) at the Month 36 visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in mean progression rates.</measure>
    <time_frame>Month 12, Month 24, Month 36</time_frame>
    <description>Between-group difference in mean progression rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Between-group difference in proportion of subjects who show &lt;-0.75 D progression and the between-group median time to a change in myopia of &lt;-0.75 D.</measure>
    <time_frame>Month 36</time_frame>
    <description>Between-group difference in proportion of subjects who show &lt;-0.75 D progression and the between-group median time to a change in myopia of &lt;-0.75 D.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">483</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>NVK-002 Concentration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Subjects will be randomized to NVK-002 Concentration 1
Stage 2: Subjects will be re-randomized to one of the three treatment arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVK-002 Concentration 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage 1: Subjects will be randomized to NVK-002 Concentration 2
Stage 2: Subjects will be re-randomized to one of the three treatment arms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stage 1: Subjects will be randomized to Vehicle (Placebo)
Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVK-002 Concentration 1</intervention_name>
    <description>Study medication will be administered, once daily (QD)</description>
    <arm_group_label>NVK-002 Concentration 1</arm_group_label>
    <other_name>NVK-002 Conc 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVK-002 Concentration 2</intervention_name>
    <description>Study medication will be administered, once daily (QD)</description>
    <arm_group_label>NVK-002 Concentration 2</arm_group_label>
    <other_name>NVK-002 Conc 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle (placebo) will be administered, once daily (QD)</description>
    <arm_group_label>Vehicle (Placebo)</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children aged 3 to â‰¤ 17.0 years.

          2. Myopia SER of at least -0.50 D and no greater than -6.00 D myopia in each eye as
             measured by cycloplegic autorefraction.

        Exclusion Criteria:

          1. If present, astigmatism more than -1.50 D in either eye.

          2. Current or history of amblyopia or strabismus.

          3. History of any disease or syndrome that predisposes the subject to severe myopia
             (e.g., Marfan syndrome, Stickler syndrome, retinopathy of prematurity).

          4. History in either eye of abnormal ocular refractive anatomy (e.g., keratoconus,
             lenticonus, spherophakia).

          5. Serious systemic illness that, in the Investigator's opinion, would render the subject
             ineligible.

          6. Chronic use (more than 3 days per week) of any topical ophthalmic medications
             (prescribed or over the-counter) other than the assigned study medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Houman Hemmati, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nevakar, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site #009</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #015</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #003</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #016</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #005</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #004</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #024</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #006</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #014</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #002</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #013</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #001</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #018</name>
      <address>
        <city>Forest Grove</city>
        <state>Oregon</state>
        <zip>97116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #011</name>
      <address>
        <city>Elkins Park</city>
        <state>Pennsylvania</state>
        <zip>19027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #017</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #008</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #007</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #012</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #020</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #021</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #104</name>
      <address>
        <city>Budapest</city>
        <zip>H - 1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #101</name>
      <address>
        <city>Dublin</city>
        <zip>D07 H6K8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site # 105</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #107</name>
      <address>
        <city>Barcelona</city>
        <zip>8950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #103</name>
      <address>
        <city>Coleraine</city>
        <zip>BT52 1HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site #106</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>child, myopia, nearsightedness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

